A New Oral Treatment For Type II Diabetes Mellitus

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 2

In brief

This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.

Key facts

Study ID

NCT00111800

Run by

GlaxoSmithKline

People needed

375

Starts

2005-04-28

Expected to finish

2006-07-21

Last updated by the study team

2018-03-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Women must not be pregnant and must not be breastfeeding.
• Have Type II diabetes.
• Not taking any medicine for diabetes, or taking one oral medicine for their diabetes.

You may not qualify if…

• Have any underlying or significant active disease that would prevent the subject from safely participating in the trial by the judgement of the study doctor.

Where it is running

• GSK Investigational Site — Pasadena, California, United States
• GSK Investigational Site — Denver, Colorado, United States
• GSK Investigational Site — Hollywood, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Marietta, Georgia, United States
• GSK Investigational Site — Honolulu, Hawaii, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Indianapolis, Indiana, United States
• GSK Investigational Site — Sunset, Louisiana, United States
• GSK Investigational Site — Oxon Hill, Maryland, United States
• GSK Investigational Site — Las Vegas, Nevada, United States
• GSK Investigational Site — Pahrump, Nevada, United States
• GSK Investigational Site — Albany, New York, United States
• GSK Investigational Site — Buffalo, New York, United States
• GSK Investigational Site — Johnson City, New York, United States
• GSK Investigational Site — Rochester, New York, United States
• GSK Investigational Site — Syracuse, New York, United States
• GSK Investigational Site — Durham, North Carolina, United States
• GSK Investigational Site — Raleigh, North Carolina, United States
• GSK Investigational Site — Cincinnati, Ohio, United States
• GSK Investigational Site — Kettering, Ohio, United States
• GSK Investigational Site — Jefferson Hills, Pennsylvania, United States
• GSK Investigational Site — Sewickley, Pennsylvania, United States
• GSK Investigational Site — Long Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.